Crystalline sirolimus-coated balloon for treating coronary artery disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter post-market observational registry enrolling consecutive adults treated with the crystalline sirolimus-coated balloon (SeQuent® SCB) during routine PCI for de novo coronary lesions or in-stent restenosis. Lesions are treated per operator discretion with the device covering at least 3 mm beyond both lesion edges, and patients are followed clinically with primary endpoint assessment at 12 months and extended follow-up to 36 months. The primary outcome is target lesion failure at 12 months, defined as target vessel myocardial infarction or ischemia-driven target lesion revascularization, and secondary outcomes include procedural success, MACE, bleeding, and subgroup analyses. No investigational randomization is performed because this is an observational post-market evaluation of real-world use.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients must provide written informed consent.
* Patients aged ≥18 years with coronary artery disease in whom, at the operator's discretion, treatment of a coronary stenosis in a native vessel (either de novo lesion or in-stent restenosis) or in a coronary bypass graft using the cSCB is indicated, in accordance with routine clinical practice.
* All treated lesions/segments (single or tandem) must receive cSCB therapy covering at least 3 mm beyond both edges of the lesion or pre-dilated segment to avoid geographic miss.
* In patients with multivessel coronary artery disease, all non-target vessels will be treated according to operator discretion: a) If more than one vessel is treated with the investigational device (SeQuent® SCB), all vessels will be documented and analyzed separately. b) Only one lesion per vessel will be included unless lesions are separated by ≥20 mm. c) Only one lesion per vessel will be included. d) If more than one lesion in the target vessel requires treatment, all lesions treated with a device different from the investigational procedure or with a device other than the investigational device (SeQuent® SCB) must be separated from the target lesion by ≥20 mm or considered as a single treated lesion according to this study protocol.

Exclusion Criteria:

* Explicit refusal by the patient to participate in the study.
* Known intolerance to sirolimus or to any component of the investigational device.
* Contraindication to any antiplatelet therapy.
* Life expectancy less than 12 months.
* Indication for surgical coronary revascularization.
* Pregnancy or breastfeeding.
* Clinical characteristics considered unsuitable for drug-coated balloon use at the operator's discretion, including: a) Hemorrhagic diathesis or other conditions such as gastrointestinal ulceration or cerebrovascular disorders restricting the use of antiplatelet therapy. b) Cardiogenic shock. c) Patients with left ventricular ejection fraction \<30% without the use of a ventricular assist device during PCI.

Angiographic exclusion criteria

* Reference vessel diameter \<2.00 mm or \>4.0 mm.
* Treatment of the left main coronary artery.
* Lesions not amenable to PCI or other interventional techniques.
* Coronary artery spasm in the absence of significant stenosis.
* Target lesion not suitable for drug-coated balloon-only PCI at the operator's discretion, including: a) Aorto-ostial lesions. b) Lesions with significant persistent residual thrombotic content visible in the vessel despite thromboaspiration. c) Treatment shortly after myocardial infarction with evidence of thrombus or impaired coronary flow.

Where it's running

• Hospital Álvaro Cunqueiro
  Vigo, Pontevedra, Spain Recruiting

Study contacts

• Study coordinator: Víctor A Jiménez Díaz, MD, MPH
• Email: victor.alfonso.jimenez.diaz@sergas.es
• Phone: +34986825564

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Smartphone AI help for prehospital ECG readings

  This study tests whether using a smartphone AI (GPT-4o) to help prehospital providers read 12-lead ECGs improves accuracy in diagnosing acute coronary syndromes and related conditions.

  Recruiting École Supérieure de Soins Ambulanciers - College of Higher Education in Prehospital Care · Murten/Morat, Canton of Fribourg · NCT07810686

• Red grape juice and metabolism in men with coronary disease

  Researchers will test whether daily red grape juice changes the blood metabolite profile in men with chronic coronary artery disease.

  Recruiting University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT07777341

• Impact of Procedural Factors on Drug-Coated Balloon Outcomes in Coronary Artery Disease

  This registry tests whether delivery time and inflation duration of drug-coated balloons affect outcomes in adults undergoing PCI for new coronary lesions.

  Recruiting at 7 sites Nanjing First Hospital, Nanjing Medical University · Chuzhou, Anhui and 6 other locations · NCT07764094

• Edoxaban vs. Apixaban in AF with CAD: Net Benefit

  This trial tests whether edoxaban-based therapy provides a similar or better overall benefit than apixaban-based therapy for stroke prevention and major bleeding in adults with atrial fibrillation and coronary artery disease.

  Recruiting Phase 4 Samsung Medical Center · Seoul · NCT07753200

• Revascularization of Calcified Coronary Arteries

  This study tests whether measuring blood flow and pressure before and after ballooning or stenting of calcified coronary arteries can help predict how well the procedure will work for adults with heart disease.

  Recruiting Aalborg University Hospital · Aalborg · NCT07724184

• Coronary thrombus modification to reduce microvascular damage during STEMI care

  This study tests whether modifying the clot in the heart arteries during primary PCI can lessen microvascular damage and myocardial injury in STEMI patients.

  Recruiting Odense University Hospital · Odense · NCT07646977

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.